Yokoyama, Osamu
Honda, Masashi
Yamanishi, Tomonori
Sekiguchi, Yuki
Fujii, Kenji
Kinoshita, Kyoko
Nakayama, Takashi
Ueno, Akikazu
Mogi, Takao http://orcid.org/0000-0002-6988-513X
Funding for this research was provided by:
GlaxoSmithKline Japan
Article History
Received: 18 May 2021
Accepted: 13 July 2021
First Online: 22 July 2021
Declarations
:
: OY has received consultancy fees from Astellas, GlaxoSmithKline, Kissei, Kyorin, Nippon Shinyaku, Pfizer, and Taiho, as well as grants from Astellas, Eisai, Kissei, Taiho, and Takeda. MH has received consultancy fees from GlaxoSmithKline. TY has received grants from Astellas, Kyorin, and Taiho. YS has no conflicts of interest. KF, KK, TN, AU and TM are employees of GlaxoSmithKline.
: The study design was approved by the institutional review board at all study sites.
: All study participants provided informed consent before enrollment.
: Patients signed informed consent regarding publishing the study data.